|
|
Post by mango on Jan 8, 2020 10:16:50 GMT -5
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative ReviewFirst online 1/4/2020 Rapid-acting inhaled insulin is available for use within a limited dose range, but large trials are needed for confirmation of efficacy. Furthermore, inhaled insulin is contraindicated in patients with chronic lung disease, is not recommended for those who smoke, costs at least twice that of other rapid-acting insulins [8], and may require additional dosing after meals [12, 13]. No mention of Afrezza in Table 3 Pharmacokinetic and pharmacodynamic properties of insulins link.springer.com/article/10.1007/s13300-019-00743-7—————————————————————————— Response: 😏 Looks like a deliberate attack on Afrezza. Must mean we are doing something right, and I expect to see more of these.
|
|
|
|
Post by mango on Jan 8, 2020 11:36:04 GMT -5
|
|
|
|
Post by agedhippie on Jan 8, 2020 12:37:06 GMT -5
Hmm.... Here we have evidence that the first author is/was affiliated with Novo Nordisk. This only further confirms what Kevin Schewe of MannKind told us via FB recently. BP is out to destroy MannKind and anyone can obviously see this in the latest hit piece above. Lol. You do realize that if you exclude all the authors of the Mannkind paper just published who who took money from Eli Lilly, Sanofi, or Novo Nordisk or who were Mannkind employees there would be nobody left? If you are in diabetes research in the US then BP is where your money comes from so this conflict exists everywhere but it doesn't mean they cannot write pro-Mannkind paper - the last paper being a case in point. |
|
|
|
Post by mango on Jan 8, 2020 12:42:16 GMT -5
Hmm.... Here we have evidence that the first author is/was affiliated with Novo Nordisk. This only further confirms what Kevin Schewe of MannKind told us via FB recently. BP is out to destroy MannKind and anyone can obviously see this in the latest hit piece above. Lol. You do realize that if you exclude all the authors of the Mannkind paper just published who who took money from Eli Lilly, Sanofi, or Novo Nordisk or who were Mannkind employees there would be nobody left? If you are in diabetes research in the US then BP is where your money comes from so this conflict exists everywhere but it doesn't mean they cannot write pro-Mannkind paper - the last paper being a case in point. This paper is clearly, without a doubt, a bias hit piece. Anyone can see that. It does not even accurately reflect current lit on Afrezza. It is also dramatically misleading and representative of misinformation. The authors claim large scale trials are needed to confirm its efficacy for christ sake. You surely aren’t this naive and close minded, aged. This only further underscores what Kevin Schewe from MannKind told us. |
|
|
|
Post by mango on Jan 8, 2020 13:09:00 GMT -5
I believe this tells us all we need to know:
Funding
Sanofi provided funding for the development of this article and the journal’s Rapid Service Fee.
Medical Writing Assistance
Jennifer L. Giel, PhD, and Meri D. Pozo, PhD, on behalf of inScience Communications, Springer Healthcare (New York, NY, USA), on the basis of input from authors, wrote and edited the manuscript. This assistance was funded by Sanofi.
Disclosures
Andrej Janež has served as a consultant and is on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme (MSD), Novo Nordisk, and Sanofi. Cristian Guja has served as a consultant for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; has received a research grant from UEFISCDI Romania; and is on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck KGaA, MSD, Novo Nordisk, and Sanofi. Asimina Mitrakou has served as a consultant for Astra Zeneca, Abbott, Bristol-Myers Squibb, and Medtronic; has received a research grant from Astra Zeneca and GlaxoSmithKline; and is on Speakers Bureaus for Boehringer Ingelheim and Novartis. Nebojsa Lalic has served as a lecturer at the Symposia of Novo Nordisk, Sanofi, Eli Lilly, Astra Zeneca, Boehringer Ingelheim, and Medtronic. Tsvetalina Tankova has served as a consultant for Astra Zeneca, Boehringer Ingelheim, MSD, and Sanofi and is on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Sanofi, Servier, and Mylan. Leszek Czupryniak has served as a consultant for Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Roche, and Sanofi and is on Speakers Bureaus for Astra Zeneca, Bioton, Boehringer Ingelheim, Eli Lilly, Gedeon Richter, Johnson & Johnson, Merck Serono, MSD, Novo Nordisk, Sanofi, and Servier. Adam G. Tabák has served as a consultant for 77 Electronika, Eli Lilly, and Sanofi and is on Speakers Bureaus for Astra Zeneca, Berlin Chemie, Eli Lilly, Novo Nordisk, and Sanofi. Martin Prazny has served as consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Roche, Sanofi, and Takeda and is on Speakers Bureaus for Abbott, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novartis, Novo Nordisk, Roche, Sanofi, and Teva. Emil Martinka has served as a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, Roche, and Sanofi and is on Speakers Bureaus for Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, and Sanofi. Lea Smircic-Duvnjak has served as a consultant for Boehringer Ingelheim, Novo Nordisk, and Sanofi and is on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Sandoz, Sanofi, and Takeda.
|
|
|
|
Post by agedhippie on Jan 8, 2020 15:34:40 GMT -5
Or indeed this disclosure section from the Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus paper:
Funding sources
Financial support for this study was provided by MannKind Corporation, Westlake Village, CA, USA.
Competing interests
Financial support for this study was provided by MannKind Corporation, Westlake Village, CA. ERS has received grant funding from Eli Lilly and Locemia, and has served as a consultant for Eli Lilly, Zucara, Sanofi, Locemia, MannKind Corporation and WebMD. LB has received research funding from Janssen Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi, and has served on speaker panels for Janssen Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi. JBM has received research funding from Medtronic, Dexcom and Sanofi; she has served as a consultant for Aegerion Pharmaceuticals Inc, Bayer, Boehringer Ingelheim, Gilead, Novo Nordisk and Sanofi, and is a member of the speakers bureau for Aegerion Pharmaceuticals Inc, Dexcom Inc, Janssen Pharmaceuticals Inc and MannKind Corporation. SRH has served on speaker panels for Eli Lilly and Novo Nordisk, and has served on advisory panels or as a consultant for Zeeland, UNEEG Medical, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi Aventis and Takeda. DMK, JBB, FMP and MLG have been or are paid employees of MannKind Corporation and may hold stock with the company.
Frank M. Pompilio was employed with MannKind Corporation during the composition and submission of this manuscript; he is no longer affiliated with MannKind Corporation.
|
|
|
|
Post by agedhippie on Jan 8, 2020 15:36:09 GMT -5
Lol. You do realize that if you exclude all the authors of the Mannkind paper just published who who took money from Eli Lilly, Sanofi, or Novo Nordisk or who were Mannkind employees there would be nobody left? If you are in diabetes research in the US then BP is where your money comes from so this conflict exists everywhere but it doesn't mean they cannot write pro-Mannkind paper - the last paper being a case in point. This paper is clearly, without a doubt, a bias hit piece. Anyone can see that. It does not even accurately reflect current lit on Afrezza. It is also dramatically misleading and representative of misinformation. The authors claim large scale trials are needed to confirm its efficacy for christ sake. You surely aren’t this naive and close minded, aged. This only further underscores what Kevin Schewe from MannKind told us. I don't think it's a good paper, but I think it falls a long way short of a hit piece. The authors are all in Europe so they could not use Afrezza if they wanted. |
|
|
|
Post by mango on Jan 8, 2020 15:41:15 GMT -5
This paper is clearly, without a doubt, a bias hit piece. Anyone can see that. It does not even accurately reflect current lit on Afrezza. It is also dramatically misleading and representative of misinformation. The authors claim large scale trials are needed to confirm its efficacy for christ sake. You surely aren’t this naive and close minded, aged. This only further underscores what Kevin Schewe from MannKind told us. I don't think it's a good paper, but I think it falls a long way short of a hit piece. The authors are all in Europe so they could not use Afrezza if they wanted. Funded by Sanofi. Whether or not the authors can or cannot use Afrezza is entirely irrelevant. 🙂 |
|
|
|
Post by mango on Jan 8, 2020 15:44:44 GMT -5
Or indeed this disclosure section from the Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus paper:Funding sources Financial support for this study was provided by MannKind Corporation, Westlake Village, CA, USA. Competing interests
Financial support for this study was provided by MannKind Corporation, Westlake Village, CA. ERS has received grant funding from Eli Lilly and Locemia, and has served as a consultant for Eli Lilly, Zucara, Sanofi, Locemia, MannKind Corporation and WebMD. LB has received research funding from Janssen Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi, and has served on speaker panels for Janssen Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi. JBM has received research funding from Medtronic, Dexcom and Sanofi; she has served as a consultant for Aegerion Pharmaceuticals Inc, Bayer, Boehringer Ingelheim, Gilead, Novo Nordisk and Sanofi, and is a member of the speakers bureau for Aegerion Pharmaceuticals Inc, Dexcom Inc, Janssen Pharmaceuticals Inc and MannKind Corporation. SRH has served on speaker panels for Eli Lilly and Novo Nordisk, and has served on advisory panels or as a consultant for Zeeland, UNEEG Medical, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi Aventis and Takeda. DMK, JBB, FMP and MLG have been or are paid employees of MannKind Corporation and may hold stock with the company. Frank M. Pompilio was employed with MannKind Corporation during the composition and submission of this manuscript; he is no longer affiliated with MannKind Corporation. And your point is? That is not a biased or misleading paper and doesn’t contain misinfo nor disinfo. The results from the clinical trial accurately support the fact that Afrezza is associated with less hypoglycemia compared with insulin Aspart. 🙂 |
|
|
|
Post by agedhippie on Jan 8, 2020 16:32:36 GMT -5
Or indeed this disclosure section from the Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus paper:Funding sources Financial support for this study was provided by MannKind Corporation, Westlake Village, CA, USA. Competing interests
Financial support for this study was provided by MannKind Corporation, Westlake Village, CA. ERS has received grant funding from Eli Lilly and Locemia, and has served as a consultant for Eli Lilly, Zucara, Sanofi, Locemia, MannKind Corporation and WebMD. LB has received research funding from Janssen Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi, and has served on speaker panels for Janssen Pharmaceuticals Inc, Merck & Co, Novo Nordisk and Sanofi. JBM has received research funding from Medtronic, Dexcom and Sanofi; she has served as a consultant for Aegerion Pharmaceuticals Inc, Bayer, Boehringer Ingelheim, Gilead, Novo Nordisk and Sanofi, and is a member of the speakers bureau for Aegerion Pharmaceuticals Inc, Dexcom Inc, Janssen Pharmaceuticals Inc and MannKind Corporation. SRH has served on speaker panels for Eli Lilly and Novo Nordisk, and has served on advisory panels or as a consultant for Zeeland, UNEEG Medical, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi Aventis and Takeda. DMK, JBB, FMP and MLG have been or are paid employees of MannKind Corporation and may hold stock with the company. Frank M. Pompilio was employed with MannKind Corporation during the composition and submission of this manuscript; he is no longer affiliated with MannKind Corporation. And your point is? That is not a biased or misleading paper and doesn’t contain misinfo nor disinfo. The results from the clinical trial accurately support the fact that Afrezza is associated with less hypoglycemia compared with insulin Aspart. 🙂 My point is that everyone writing these papers takes money from big pharma so the assumption that anything you don't like is bought and paid for if the author discloses that they took money from BP is a bit silly. And to your other point; this paper was funded by Mannkind, does that mean it's also biased? |
|
|
|
Post by mango on Jan 8, 2020 16:40:11 GMT -5
And your point is? That is not a biased or misleading paper and doesn’t contain misinfo nor disinfo. The results from the clinical trial accurately support the fact that Afrezza is associated with less hypoglycemia compared with insulin Aspart. 🙂 My point is that everyone writing these papers takes money from big pharma so the assumption that anything you don't like is bought and paid for if the author discloses that they took money from BP is a bit silly. And to your other point; this paper was funded by Mannkind, does that mean it's also biased? The paper that was funded by MannKind is actually not biased as it accurately reflects the clinical trial data and factual, accurate information. Some people are just not good at discerning information. The Sanofi article is clearly biased and also contains misinformation. |
|
|
|
Post by peppy on Jan 8, 2020 16:53:38 GMT -5
And your point is? That is not a biased or misleading paper and doesn’t contain misinfo nor disinfo. The results from the clinical trial accurately support the fact that Afrezza is associated with less hypoglycemia compared with insulin Aspart. 🙂 My point is that everyone writing these papers takes money from big pharma so the assumption that anything you don't like is bought and paid for if the author discloses that they took money from BP is a bit silly. And to your other point; this paper was funded by Mannkind, does that mean it's also biased?  yes, it has been a shock to learn all the things we were taught were lies. |
|
|
|
Post by mango on Jan 8, 2020 16:59:23 GMT -5
Aged, I am going to go as far as saying MannKind has never funded a single biased publication and has never funded a single publication that also contains misinfo and/or disinfo—especially not one similar to all the publications throughout the years funded by Sanofi, Novo, Lilly and others that soft bash Afrezza and included misinfo and/or misinfo.
I’ve never read a publication funded by MannKind that soft bashed any of the RAAs and/or included misinfo and/or disinfo, so I would love for you to show me one! 🙂
|
|
|
|
Post by agedhippie on Jan 8, 2020 17:21:04 GMT -5
My point is that everyone writing these papers takes money from big pharma so the assumption that anything you don't like is bought and paid for if the author discloses that they took money from BP is a bit silly. And to your other point; this paper was funded by Mannkind, does that mean it's also biased? yes, it has been a shock to learn all the things we were taught were lies. It's how an awful lot of papers are funded. That doesn't mean they are biased. For the most part if you are an academic the funding for your research comes from all over the place. If there was an author who had just one funding source (and wasn't an employee) I would be a lot more suspicious - or think they were just starting out. Maybe this GIF is appropriate   |
|
|
|
Post by agedhippie on Jan 8, 2020 17:25:15 GMT -5
Aged, I am going to go as far as saying MannKind has never funded a single biased publication and has never funded a single publication that also contains misinfo and/or disinfo—especially not one similar to all the publications throughout the years funded by Sanofi, Novo, Lilly and others that soft bash Afrezza and included misinfo and/or misinfo. I’ve never read a publication funded by MannKind that soft bashed any of the RAAs and/or included misinfo and/or disinfo, so I would love for you to show me one! 🙂 I haven't read them all, but I can believe it. Papers all contain an inherent bias towards the authors position because that is what they believe otherwise they wouldn't be writing the paper. There is no malice in that. I would suggest people never make the mistake of reading any paper uncritically. |
|
